Richard Daniell, Executive VP, European Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), sold 97,258 shares at $13.52 ($1.3M) on 2024-03-05, disclosed to the SEC on 2024-03-07.
Scheduled sale ($1.3M) by Executive VP, European Commercial under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.52 | 22,576 | $305K | 23.2% |
| 2 | $13.52 | 22,576 | $305K | 23.2% |
| 3 | $13.52 | 26,053 | $352K | 26.8% |
| 4 | $13.52 | 26,053 | $352K | 26.8% |
| Total | $13.52 avg | 97,258 | $1.3M | 100% |
| Filing → |
| TEVA | SELL | 2026-03-06 | $6.0M | — | Filing → |
| TEVA | SELL | 2026-03-05 | $8.3M | — | Filing → |
| TEVA | SELL | 2025-12-11 | $6.6M | — | Filing → |